



NAoMe

National Audit of
Metastatic Breast Cancer

NAoMe, Clinical Effectiveness Unit

Royal College of Surgeons of England
38-43 Lincoln's Inn Fields
London WC2A 3PE

E: BreastCancerAudits@rcseng.ac.uk

T: 020 7869 6610

X NAoMe_news

Key COSD data items for collection 2023/2024

Demographics	England – COSD V9/10
NHS NUMBER (for linkage of datasets)	CR0010 NHS NUMBER
AGE	CR0100 PERSON BIRTH DATE
GENDER	CR3170 PERSON STATED GENDER CODE
DEPRIVATION	CR0080 POSTCODE OF USUAL ADDRESS (AT DIAGNOSIS)
ETHNICITY	CR0150 ETHNIC CATEGORY
Patient fitness	
PERFORMANCE STATUS	CR0510 PERFORMANCE STATUS (ADULT)
Process	
REFERRAL SOURCE – INITIAL DIAGNOSIS	CR1600 SOURCE OF REFERRALS FOR OUTPATIENTS
REFERRAL SOURCE – RECURRENCE DIAGNOSIS	CR0300 SOURCE OF REFERRAL FOR NON PRIMARY PATHWAY
CONTACT TIMINGS	CR0230 DATE FIRST SEEN
	CR1360 DATE FIRST SEEN (CANCER SPECIALIST)
	CR7400 DATE FIRST SEEN - NON PRIMARY CANCER PATHWAY
ACCESS TO SUPPORT – CLINICAL NURSE SPECIALIST	CR2050 CLINICAL NURSE SPECIALIST INDICATION CODE
ACCESS TO SUPPORT – PALLIATIVE CARE	CR1550 PALLIATIVE CARE SPECIALIST SEEN INDICATOR (CANCER RECURRENCE)
DISCUSSED AT / CARE MANAGED BY MDT	CR3080 MULTIDISCIPLINARY TEAM MEETING DATE
	CR0430 MULTIDISCIPLINARY TEAM MEETING DATE (CANCER)
	CR3190 MULTIDISCIPLINARY TEAM MEETING TYPE
Diagnosis details	
INITIAL/PRIMARY DIAGNOSIS	
DATE OF DIAGNOSIS	CR2030 DATE OF DIAGNOSIS (CLINICALLY AGREED)
DIAGNOSIS CODE	CR0370 PRIMARY DIAGNOSIS (ICD)
PRETREATMENT M STAGE DETAILS	CR0560 M CATEGORY (FINAL PRE-TREATMENT)
	CR3120 STAGE DATE (FINAL PRETREATMENT STAGE)
SITE OF METASTASES	CR6970 METASTATIC SITE
INTEGRATED M STAGE DETAILS	CR0640 M CATEGORY (INTEGRATED STAGE)
	CR3130 STAGE DATE (INTEGRATED STAGE)
PATHOLOGICAL M STAGE DETAILS	pCR0930 M CATEGORY (PATHOLOGICAL)
	pCR1010 SAMPLE COLLECTION DATE
MOLECULAR MARKERS – ER	pBR4220 ER STATUS
	pBR4230 ER ALLRED SCORE
MOLECULAR MARKERS – PR	pBR4290 PR STATUS
	pBR4300 PR ALLRED SCORE
MOLECULAR MARKERS – HER2	pBR4280 HER2 STATUS
	pBR4310 HER2 ISH STATUS
RECURRENT DIAGNOSIS	



NATCAN

National Cancer Audit
Collaborating Centre

NAoMe key data items V1 – December 2023



NAoMe

National Audit of
Metastatic Breast Cancer

NAoMe, Clinical Effectiveness Unit

Royal College of Surgeons of England
38-43 Lincoln's Inn Fields
London WC2A 3PE

E: BreastCancerAudits@rcseng.ac.uk

T: 020 7869 6610

X NAoMe_news

DATE OF RECURRENCE	CR6500 DATE OF NON PRIMARY CANCER PATHWAY (CLINICALLY AGREED)
RECURRENCE DETAILS	CR6520 RECURRENCE OR METASTATIC TYPE
SITE OF METASTASES	CR1590 METASTATIC SITE
PRIMARY DIAGNOSIS DETAILS	CR7100 ORIGINAL PRIMARY DIAGNOSIS (ICD)
Treatment	
CANCER CARE PLAN	CR0460 CANCER CARE PLAN INTENT
	CR0470 PLANNED CANCER TREATMENT TYPE
REASON FOR NO TREATMENT	CR0490 NO CANCER TREATMENT REASON

Please note, as of 1 January 2018, TNMv8 should be submitted.



NATCAN

National Cancer Audit
Collaborating Centre

NAoMe key data items V1 – December 2023